NASDAQ:REPL

Replimune Group (REPL) Stock Price, News & Analysis

Replimune Group logo
$19.95 +0.26 (+1.34%)
As of 01:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Replimune Group Stock (NASDAQ:REPL)

Advanced

Key Stats

Today's Range
$19.33
▼
$20.12
50-Day Range
$10.86
▼
$23.28
52-Week Range
$1.50
▼
$23.54
Volume
768,628 shs
Average Volume
4.27 million shs
Market Capitalization
$1.89 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.17
Consensus Rating
Moderate Buy

Company Overview

Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer.

The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches. These programs remain investigational and are being evaluated in clinical studies.

Founded in 2015, Replimune is headquartered in Woburn, Massachusetts. Its work centers on research and clinical development rather than marketed products or services.

AI Generated. May Contain Errors.

Replimune Group Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

REPL MarketRank™: 
1.43369175627 of 5 stars

Replimune Group scored higher than 29% of companies evaluated by MarketBeat, and ranked 752nd out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Replimune Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 2 sell ratings.

  • Downside Risk

    Replimune Group has a consensus price target of $18.17, representing about 8.6% downside from its current price of $19.88.

  • Amount of Analyst Coverage

    Replimune Group has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Replimune Group's stock forecast and price target.
  • Earnings Growth

    Earnings for Replimune Group are expected to grow in the coming year, from ($2.40) to ($1.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Replimune Group is -7.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Replimune Group is -7.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Replimune Group has a P/B Ratio of 9.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Replimune Group's valuation and earnings.
  • Percentage of Shares Shorted

    27.44% of the float of Replimune Group has been sold short.
  • Short Interest Ratio / Days to Cover

    Replimune Group has a short interest ratio ("days to cover") of 8.31.
  • Change versus previous month

    Short interest in Replimune Group has recently increased by 6.23%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Replimune Group does not currently pay a dividend.

  • Dividend Growth

    Replimune Group does not have a long track record of dividend growth.

  • News Sentiment

    Replimune Group has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Replimune Group this week, compared to 6 articles on an average week.
  • Search Interest

    6 people have searched for REPL on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Replimune Group to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Replimune Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $521,860.00 in company stock.

  • Percentage Held by Insiders

    5.40% of the stock of Replimune Group is held by insiders.

  • Percentage Held by Institutions

    92.53% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Replimune Group's insider trading history.
Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

REPL Stock News Headlines

Replimune Earnings Call Highlights Rapid TUDRIQEV Launch
Replimune Group (NASDAQ:REPL) Stock Falls 4.8% After Insider Selling
Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
Cramer's lightning round: Buy FedEx Freight
See More Headlines

REPL Stock Analysis - Frequently Asked Questions

Replimune Group's stock was trading at $9.72 at the beginning of the year. Since then, REPL stock has increased by 104.5% and is now trading at $19.88.

Replimune Group, Inc. (NASDAQ:REPL) released its earnings results on Wednesday, October, 28th. The company reported ($0.54) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.24.
Read the conference call transcript
.

Replimune Group (REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Top institutional shareholders of Replimune Group include State Street Corp (4.40%), Marshall Wace LLP (4.02%), Goldman Sachs Group Inc. (3.50%) and Jump Financial LLC (0.52%). Insiders that own company stock include Robert Coffin, Philip Astley-Sparke, Colin Love, Sushil Patel, Konstantinos Xynos, Emily Luisa Hill, Christopher Sarchi, Andrew Schwendenman, Kapil Dhingra and Joseph P Slattery.
View institutional ownership trends
.

Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Replimune Group investors own include Palantir Technologies (PLTR), Marvell Technology (MRVL), Micron Technology (MU), Regeneron Pharmaceuticals (REGN), Archer Aviation (ACHR), Amprius Technologies (AMPX) and Chevron (CVX).

Company Calendar

Last Earnings
10/28/2026
Today
11/18/2026
Next Earnings (Estimated)
2/02/2027
Fiscal Year End
3/31/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:REPL
CIK
1737953
Fax
N/A
Employees
465
Year Founded
2015

Price Target and Rating

High Price Target
$31.00
Low Price Target
$2.00
Potential Upside/Downside
-8.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$313.94 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-157.78%
Return on Assets
-83.89%

Debt

Debt-to-Equity Ratio
0.59
Current Ratio
7.11
Quick Ratio
6.90

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.16 per share
Price / Book
9.20

Miscellaneous

Outstanding Shares
94,800,000
Free Float
89,681,000
Market Cap
$1.88 billion
Optionable
Optionable
Beta
0.93
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:REPL) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners